# reload+after+2024-01-19 23:44:16.989735
address1§151 Oyster Point Boulevard
address2§Suite 400
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 515 3185
fax§650 351 0353
website§https://www.cytomx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company's pipeline comprises therapeutic candidates across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies, and immune modulators, such as cytokines and checkpoint inhibitors. CX-2029 is an investigational conditional ADC directed toward CD71. Its clinical pipeline also includes cancer immunotherapeutic candidates against validated targets, such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, as well as CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, it has a preclinical portfolio of wholly owned assets, including CX-801, an interferon alpha-2b Probody cytokine that has potential applicability in immuno-oncology sensitive, as well as insensitive (cold) tumors and CX-2051, an ADC directed toward EpCAM with potential applicability across multiple EpCAM-expressing epithelial cancers. The company has strategic collaborations with various leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. The company was founded in 2008 and is headquartered in South San Francisco, California.
fullTimeEmployees§116
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Sean A. McCarthy DPHIL', 'age': 56, 'title': 'Chairman & CEO', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 1025446, 'exercisedValue': 0, 'unexercisedValue': 4289}, {'maxAge': 1, 'name': 'Mr. Lloyd A. Rowland Jr., J.D.', 'age': 66, 'title': 'Senior VP, General Counsel, Chief Compliance Officer & Secretary', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 608718, 'exercisedValue': 0, 'unexercisedValue': 150}, {'maxAge': 1, 'name': 'Mr. Jeffrey  Landau B.S., M.B.A.', 'age': 45, 'title': 'Senior VP, Head of Strategy & Chief Business Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 581683, 'exercisedValue': 0, 'unexercisedValue': 150}, {'maxAge': 1, 'name': 'Mr. Christopher W. Ogden', 'age': 39, 'title': 'Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marcia P. Belvin Ph.D.', 'title': 'Senior VP & Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Chau  Cheng M.B.A., Ph.D.', 'title': 'Vice President of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Danielle  Olander-Moghadassian', 'title': 'Senior VP & Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Leslie  Robbins', 'title': 'Senior Vice President of Intellectual Property', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Yu-Waye  Chu M.D.', 'age': 55, 'title': 'Chief Medical Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Dawn  Benson', 'title': 'Senior Vice President of Quality & Product Manufacturing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§9
compensationRisk§8
shareHolderRightsRisk§3
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.871
priceToSalesTrailing12Months§1.0678058
currency§USD
dateShortInterest§1702598400
forwardEps§-0.22
pegRatio§28.7
exchange§NMS
quoteType§EQUITY
shortName§CytomX Therapeutics, Inc.
longName§CytomX Therapeutics, Inc.
firstTradeDateEpochUtc§1444311000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c5953a3e-48a3-3ef1-b8e7-58afa2ecd58e
gmtOffSetMilliseconds§-18000000
targetHighPrice§3.5
targetLowPrice§1.6
targetMeanPrice§2.61
targetMedianPrice§2.63
recommendationMean§2.8
recommendationKey§hold
numberOfAnalystOpinions§6
quickRatio§1.339
grossMargins§1.0
ebitdaMargins§-0.05689
trailingPegRatio§None
